

Conditions	Interventions	Outcome Measures	Number Enrolled	Study Start	Primary Completion	Study Completion
<ul style="list-style-type: none"> Bladder Cancer Hematuria 	<ul style="list-style-type: none"> Diagnostic Test: AssureMDx 	<ul style="list-style-type: none"> Performance of a panel of methylation markers for the detection of bladder cancer in patient presenting with hematuria. Predictiveness of a panel of methylation markers combined with clinical risk factors for the detection of bladder cancer. 	700	March 31, 2017	April 30, 2018	May 31, 2018
<ul style="list-style-type: none"> Prostate Cancer 	<ul style="list-style-type: none"> Diagnostic Test: ConfirmMDx Diagnostic Test: SelectMDx 	<ul style="list-style-type: none"> Validate ConfirmMDx for Prostate Cancer to predict the outcome of repeat biopsy Comparison between clinical and pathological outcomes 	1000	March 31, 2017	April 30, 2018	October 30, 2018
<ul style="list-style-type: none"> Prostate Cancer 		<ul style="list-style-type: none"> The primary objective is to demonstrate the clinical utility of the ConfirmMDx test Compare rebiopsy rates assay negative results in cases and controls Compare rebiopsy rates in assay positive group vs standard of care (and 4 more...) 	600	September 2014	May 2018	May 2018